Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S2254887422001047?via=ihub
Available online 19 December 2022 This work aims to assess the effect of weekly subcutaneous semaglutide on biomarkers of metabolic-associated fatty liver disease (MAFLD), namely the hepatic steatosis index (HSI)...
/>
Conclusions: These results show that weekly subcutaneous semaglutide had a beneficial effect on liver steatosis that went beyond glucose control. Its effects were mainly related to weight loss, a decline in biomarkers, and improvements in insulin sensitivity. For many patients, early detection is essential for improving MAFLD outcomes and may...
Share
Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36542260/
Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands...
Conclusions: Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.
Share
Semaglutide-Associated Acute Interstitial Nephritis: A Case Report
Source : https://www.kidneymedicinejournal.org/article/S2590-0595(22)00193-5/fulltext
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). These agents have proven benefits...
Conclusion: Currently, with semaglutide prescription, monitoring of kidney function is limited to patients with severe adverse gastrointestinal reactions.
Share
-
Dr Hamid3yrGlucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD)
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36502289/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
Share
-
Dr Hamid3yrpaper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in P | CLEP
Obesity is a chronic disease with serious health consequences; it can lead to insulin resistance, hypertension, and dyslipidemia, associated with complications such as type 2 diabetes, cardiovascular disease, and non-alcoholic...
Conclusion: This meta-analysis indicates that all GLP-1RAs were more efficacious than placebo in people with obesity or overweight on efficacy. Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia. In addition, although...
Share